Treating progressive disseminated histoplasmosis in people living with HIV.
Amphotericin B
/ adverse effects
Anti-HIV Agents
/ therapeutic use
Antifungal Agents
/ adverse effects
Cohort Studies
Deoxycholic Acid
Drug Administration Schedule
Fluconazole
/ therapeutic use
HIV Infections
/ complications
Histoplasmosis
/ drug therapy
Humans
Induction Chemotherapy
Itraconazole
/ therapeutic use
Kidney
/ drug effects
Liposomes
Maintenance Chemotherapy
Randomized Controlled Trials as Topic
Journal
The Cochrane database of systematic reviews
ISSN: 1469-493X
Titre abrégé: Cochrane Database Syst Rev
Pays: England
ID NLM: 100909747
Informations de publication
Date de publication:
28 04 2020
28 04 2020
Historique:
entrez:
29
4
2020
pubmed:
29
4
2020
medline:
21
8
2020
Statut:
epublish
Résumé
Progressive disseminated histoplasmosis (PDH) is a serious fungal infection that affects people living with HIV. The best way to treat the condition is unclear. We assessed evidence in three areas of equipoise. 1. Induction. To compare efficacy and safety of initial therapy with liposomal amphotericin B versus initial therapy with alternative antifungals. 2. Maintenance. To compare efficacy and safety of maintenance therapy with 12 months of oral antifungal treatment with shorter durations of maintenance therapy. 3. Antiretroviral therapy (ART). To compare the outcomes of early initiation versus delayed initiation of ART. We searched the Cochrane Infectious Diseases Group Specialized Register; Cochrane CENTRAL; MEDLINE (PubMed); Embase (Ovid); Science Citation Index Expanded, Conference Proceedings Citation Index-Science, and BIOSIS Previews (all three in the Web of Science); the WHO International Clinical Trials Registry Platform, ClinicalTrials.gov, and the ISRCTN registry, all up to 20 March 2020. We evaluated studies assessing the use of liposomal amphotericin B and alternative antifungals for induction therapy; studies assessing the duration of antifungals for maintenance therapy; and studies assessing the timing of ART. We included randomized controlled trials (RCT), single-arm trials, prospective cohort studies, and single-arm cohort studies. Two review authors assessed eligibility and risk of bias, extracted data, and assessed certainty of evidence. We used the Cochrane 'Risk of bias' tool to assess risk of bias in randomized studies, and ROBINS-I tool to assess risk of bias in non-randomized studies. We summarized dichotomous outcomes using risk ratios (RRs), with 95% confidence intervals (CI). We identified 17 individual studies. We judged eight studies to be at critical risk of bias, and removed these from the analysis. 1. Induction We found one RCT which compared liposomal amphotericin B to deoxycholate amphotericin B. Compared to deoxycholate amphotericin B, liposomal amphotericin B may have higher clinical success rates (RR 1.46, 95% CI 1.01 to 2.11; 1 study, 80 participants; low-certainty evidence). Compared to deoxycholate amphotericin B, liposomal amphotericin B has lower rates of nephrotoxicity (RR 0.25, 95% CI 0.09 to 0.67; 1 study, 77 participants; high-certainty evidence). We found very low-certainty evidence to inform comparisons between amphotericin B formulations and azoles for induction therapy. 2. Maintenance We found no eligible study that compared less than 12 months of oral antifungal treatment to 12 months or greater for maintenance therapy. For both induction and maintenance, fluconazole performed poorly in comparison to other azoles. 3. ART We found one study, in which one out of seven participants in the 'early' arm and none of the three participants in the 'late' arm died. Liposomal amphotericin B appears to be a better choice compared to deoxycholate amphotericin B for treating PDH in people with HIV; and fluconazole performed poorly compared to other azoles. Other treatment choices for induction, maintenance, and when to start ART have no evidence, or very low certainty evidence. PDH needs prospective comparative trials to help inform clinical decisions.
Sections du résumé
BACKGROUND
Progressive disseminated histoplasmosis (PDH) is a serious fungal infection that affects people living with HIV. The best way to treat the condition is unclear.
OBJECTIVES
We assessed evidence in three areas of equipoise. 1. Induction. To compare efficacy and safety of initial therapy with liposomal amphotericin B versus initial therapy with alternative antifungals. 2. Maintenance. To compare efficacy and safety of maintenance therapy with 12 months of oral antifungal treatment with shorter durations of maintenance therapy. 3. Antiretroviral therapy (ART). To compare the outcomes of early initiation versus delayed initiation of ART.
SEARCH METHODS
We searched the Cochrane Infectious Diseases Group Specialized Register; Cochrane CENTRAL; MEDLINE (PubMed); Embase (Ovid); Science Citation Index Expanded, Conference Proceedings Citation Index-Science, and BIOSIS Previews (all three in the Web of Science); the WHO International Clinical Trials Registry Platform, ClinicalTrials.gov, and the ISRCTN registry, all up to 20 March 2020.
SELECTION CRITERIA
We evaluated studies assessing the use of liposomal amphotericin B and alternative antifungals for induction therapy; studies assessing the duration of antifungals for maintenance therapy; and studies assessing the timing of ART. We included randomized controlled trials (RCT), single-arm trials, prospective cohort studies, and single-arm cohort studies.
DATA COLLECTION AND ANALYSIS
Two review authors assessed eligibility and risk of bias, extracted data, and assessed certainty of evidence. We used the Cochrane 'Risk of bias' tool to assess risk of bias in randomized studies, and ROBINS-I tool to assess risk of bias in non-randomized studies. We summarized dichotomous outcomes using risk ratios (RRs), with 95% confidence intervals (CI).
MAIN RESULTS
We identified 17 individual studies. We judged eight studies to be at critical risk of bias, and removed these from the analysis. 1. Induction We found one RCT which compared liposomal amphotericin B to deoxycholate amphotericin B. Compared to deoxycholate amphotericin B, liposomal amphotericin B may have higher clinical success rates (RR 1.46, 95% CI 1.01 to 2.11; 1 study, 80 participants; low-certainty evidence). Compared to deoxycholate amphotericin B, liposomal amphotericin B has lower rates of nephrotoxicity (RR 0.25, 95% CI 0.09 to 0.67; 1 study, 77 participants; high-certainty evidence). We found very low-certainty evidence to inform comparisons between amphotericin B formulations and azoles for induction therapy. 2. Maintenance We found no eligible study that compared less than 12 months of oral antifungal treatment to 12 months or greater for maintenance therapy. For both induction and maintenance, fluconazole performed poorly in comparison to other azoles. 3. ART We found one study, in which one out of seven participants in the 'early' arm and none of the three participants in the 'late' arm died.
AUTHORS' CONCLUSIONS
Liposomal amphotericin B appears to be a better choice compared to deoxycholate amphotericin B for treating PDH in people with HIV; and fluconazole performed poorly compared to other azoles. Other treatment choices for induction, maintenance, and when to start ART have no evidence, or very low certainty evidence. PDH needs prospective comparative trials to help inform clinical decisions.
Identifiants
pubmed: 32343003
doi: 10.1002/14651858.CD013594
pmc: PMC7192368
doi:
Substances chimiques
Anti-HIV Agents
0
Antifungal Agents
0
Liposomes
0
liposomal amphotericin B
0
Deoxycholic Acid
005990WHZZ
Itraconazole
304NUG5GF4
Amphotericin B
7XU7A7DROE
Fluconazole
8VZV102JFY
Types de publication
Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
CD013594Informations de copyright
Copyright © 2020 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.
Références
Mycoses. 2017 Jan;60(1):59-65
pubmed: 27625302
Clin Infect Dis. 1996 Nov;23(5):996-1001
pubmed: 8922792
Leuk Lymphoma. 2015;56(10):2889-94
pubmed: 25629990
AIDS Patient Care STDS. 2013 Feb;27(2):71-6
pubmed: 23373662
J Cutan Pathol. 2002 Apr;29(4):215-25
pubmed: 12028154
Cochrane Database Syst Rev. 2018 Jul 24;7:CD009012
pubmed: 30039850
J Pediatric Infect Dis Soc. 2013 Dec;2(4):293-308
pubmed: 26619492
Am J Med. 1994 Jun;96(6):504-8
pubmed: 8017447
Mycoses. 2013 May;56(3):212-21
pubmed: 23216676
Clin Exp Dermatol. 2007 May;32(3):250-5
pubmed: 17397349
Rev Iberoam Micol. 2017 Apr - Jun;34(2):94-98
pubmed: 28391953
An Med Interna. 1998 Oct;15(10):523-7
pubmed: 9844226
Mycoses. 2013 Sep;56(5):520-6
pubmed: 23496116
Mycopathologia. 1991 Jul;115(1):13-8
pubmed: 1922265
Drugs. 2013 Jun;73(9):919-34
pubmed: 23729001
Sangre (Barc). 1993 Feb;38(1):51-5
pubmed: 8470036
Diagn Microbiol Infect Dis. 2008 Oct;62(2):151-6
pubmed: 18597967
Mycoses. 2014 Jul;57(7):406-13
pubmed: 24612078
Gac Med Mex. 2003 May-Jun;139(3):270-5
pubmed: 12872420
Drugs. 2009;69(3):361-92
pubmed: 19275278
Int J STD AIDS. 2014 Aug;25(9):656-61
pubmed: 24598976
Mycoses. 2008 Mar;51(2):136-40
pubmed: 18254750
South Med J. 1990 Jun;83(6):624-30
pubmed: 2356493
J Infect. 2007 Apr;54(4):319-27
pubmed: 16824608
Ann Intern Med. 1993 Apr 15;118(8):610-6
pubmed: 8383934
J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Oct 1;16(2):100-7
pubmed: 9358104
Clin Infect Dis. 2004 Jan 1;38(1):134-8
pubmed: 14679459
Semin Respir Infect. 1986 Mar;1(1):1-8
pubmed: 3317594
Am J Med. 1992 Feb;92(2):153-60
pubmed: 1543199
Clin Infect Dis. 2016 Aug 1;63(3):356-62
pubmed: 27169478
Clin Infect Dis. 2005 Apr 15;40(8):1199-202
pubmed: 15791523
J Antimicrob Chemother. 2004 Nov;54(5):849-53
pubmed: 15456733
Curr Infect Dis Rep. 2017 Aug 22;19(10):36
pubmed: 28831671
Drugs. 2005;65(11):1553-67; discussion 1568-9
pubmed: 16033292
Int J Infect Dis. 2006 Jan;10(1):66-71
pubmed: 16242368
Cochrane Database Syst Rev. 2015 Nov 23;(11):CD010481
pubmed: 26595825
Medicine (Baltimore). 2014 Jan;93(1):11-18
pubmed: 24378739
Medicine (Baltimore). 2008 Jul;87(4):193-202
pubmed: 18626302
J Infect Dis. 2002 Dec 1;186(11):1655-60
pubmed: 12447743
Pediatr Transplant. 2018 Nov;22(7):e13274
pubmed: 30076688
Aust N Z J Med. 1995 Feb;25(1):56
pubmed: 7786250
MMWR Recomm Rep. 2004 Dec 17;53(RR-15):1-112
pubmed: 15841069
Medicine (Baltimore). 2018 Mar;97(13):e0245
pubmed: 29595679
Clin Infect Dis. 2020 Feb 3;70(4):643-652
pubmed: 30921453
Expert Opin Drug Saf. 2010 Sep;9(5):723-42
pubmed: 20345324
Open Forum Infect Dis. 2015 Feb 20;2(1):ofu116
pubmed: 26034750
Open Forum Infect Dis. 2015 Apr 15;2(2):ofv055
pubmed: 26380347
Emerg Microbes Infect. 2019;8(1):1139-1145
pubmed: 31364950
Antimicrob Agents Chemother. 2002 Jan;46(1):248-50
pubmed: 11751146
Rev Inst Med Trop Sao Paulo. 2007 May-Jun;49(3):135-8
pubmed: 17625688
Am J Trop Med Hyg. 2017 Jul;97(1):42-48
pubmed: 28719316
Ann Pharmacother. 2001 Jun;35(6):720-9
pubmed: 11408991
South Med J. 1992 Dec;85(12):1166-70
pubmed: 1470957
BMJ. 2016 Oct 12;355:i4919
pubmed: 27733354
Arch Intern Med. 1985 Dec;145(12):2272
pubmed: 4074049
AIDS. 2008 May 31;22(9):1047-53
pubmed: 18520348
PLoS One. 2009;4(5):e5575
pubmed: 19440326
PLoS Negl Trop Dis. 2014 Jan 30;8(1):e2638
pubmed: 24498446
Oral Dis. 1997 Sep;3(3):184-7
pubmed: 9467363
Rev Soc Bras Med Trop. 1997 Mar-Apr;30(2):119-24
pubmed: 9148334
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2002 Jun;93(6):654-9
pubmed: 12142871
J Infect Dis. 2000 Aug;182(2):545-50
pubmed: 10915087
Antimicrob Agents Chemother. 2001 Aug;45(8):2354-7
pubmed: 11451696
Clin Infect Dis. 2007 Oct 1;45(7):807-25
pubmed: 17806045
Clin Infect Dis. 2001 Dec 1;33(11):1910-3
pubmed: 11692303
Cochrane Database Syst Rev. 2018 Jul 25;7:CD005647
pubmed: 30045416
Lancet. 1992 Sep 12;340(8820):648-51
pubmed: 1355218
Diagn Microbiol Infect Dis. 2006 Jul;55(3):195-201
pubmed: 16545932
Clin Infect Dis. 2001 Apr 15;32(8):1215-20
pubmed: 11283812
Pathol Biol (Paris). 1989 Jun;37(5 Pt 2):690-3
pubmed: 2552380
Chest. 1988 May;93(5):916-21
pubmed: 3359846
PLoS One. 2016 Jun 07;11(6):e0153921
pubmed: 27271083
Am J Med. 1997 Sep;103(3):223-32
pubmed: 9316555
PLoS One. 2010 Jul 01;5(7):e11416
pubmed: 20617176
Ann Intern Med. 2002 Jul 16;137(2):105-9
pubmed: 12118965
Medicine (Baltimore). 2007 May;86(3):162-169
pubmed: 17505255
Open Forum Infect Dis. 2015 Mar 30;2(1):ofv025
pubmed: 26034774
Am J Med. 1995 Apr;98(4):336-42
pubmed: 7709945
Mycopathologia. 2020 Apr;185(2):339-346
pubmed: 32078723
East Afr Med J. 2009 Dec;86(12 Suppl):S102-5
pubmed: 21591519
Int J Infect Dis. 2013 Aug;17(8):e615-20
pubmed: 23474174
Clin Infect Dis. 1996 Nov;23(5):1187-8
pubmed: 8922832
Medicina (B Aires). 2016;76(6):332-337
pubmed: 27959839
Am J Trop Med Hyg. 2005 Sep;73(3):576-82
pubmed: 16172484
Rev Chilena Infectol. 2018;35(5):560-565
pubmed: 30725004
Am J Med. 1992 Nov;93(5):489-97
pubmed: 1332471
J Assoc Physicians India. 2005 Mar;53:185-9
pubmed: 15926599
Med Mycol. 2019 Oct 1;57(7):791-799
pubmed: 30668766
Med Decis Making. 1997 Oct-Dec;17(4):373-81
pubmed: 9343795
Med Klin (Munich). 1991 Dec;86 Suppl 1:8-10
pubmed: 1663205
AIDS. 2014 Jul 31;28(12):1848-50
pubmed: 25006830
PLoS Negl Trop Dis. 2014 Aug 21;8(8):e3100
pubmed: 25144374
Clin Exp Dermatol. 2009 Jun;34(4):481-6
pubmed: 19040507
Semin Respir Infect. 1989 Jun;4(2):139-46
pubmed: 2749035
J Assoc Physicians India. 2012 Oct;60:25-8
pubmed: 23777021
Mycoses. 1992 Nov-Dec;35(11-12):281-7
pubmed: 1338877
Clin Vaccine Immunol. 2011 Apr;18(4):661-6
pubmed: 21307278
Rev Iberoam Micol. 2004 Jun;21(2):75-8
pubmed: 15538831
Ann N Y Acad Sci. 1988;544:443-50
pubmed: 3063181
Trans R Soc Trop Med Hyg. 2012 Aug;106(8):484-8
pubmed: 22703696
Enferm Infecc Microbiol Clin. 2004 Mar;22(3):156-9
pubmed: 14987536
Ann Intern Med. 1989 Oct 15;111(8):655-9
pubmed: 2802421
Eur J Clin Pharmacol. 2013 Jul;69(7):1351-68
pubmed: 23361383
Laryngoscope. 1995 Sep;105(9 Pt 1):919-23
pubmed: 7666725
J Antimicrob Chemother. 2006 Jun;57(6):1235-9
pubmed: 16627592
Am J Med. 1988 Aug;85(2):152-8
pubmed: 3400691
Clin Infect Dis. 2004 May 15;38(10):1485-9
pubmed: 15156489